Abstract
Major depressive disorder is a common mental disease with unknown aetiology. Recent pre-clinical and clinical studies have suggested that the receptor tropomyosin related kinase B (TrkB) and its ligand, brain derived neurotrophic factor (BDNF), play essential roles in the pathogenesis and treatment of major depression. BDNF-TrkB pathway down-regulation may be the most important cause of major depression, while treatments that activate this pathway may improve depressive symptoms. Antidepressants, the main biological treatment for major depression, have been reported to increase central BDNF levels. However, a substantial proportion of depressed patients do not improve clinically despite appropriate antidepressant treatment and, in rare cases, antidepressants can induce or increase suicidal tendencies. In this report, several possible mechanisms relating to BDNF-TrkB signaling are proposed to account for these adverse effects of antidepressants. In addition, several strategies that may increase BDNF-TrkB signaling are proposed for the improved treatment of major depression.
Keywords: Major depressive disorder, receptor tropomyosin related kinase B, brain derived neurotrophic factor, antidepressant, p75 neurotrophin receptor
Current Signal Transduction Therapy
Title: A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression
Volume: 2 Issue: 3
Author(s): Shih-Jen Tsai
Affiliation:
Keywords: Major depressive disorder, receptor tropomyosin related kinase B, brain derived neurotrophic factor, antidepressant, p75 neurotrophin receptor
Abstract: Major depressive disorder is a common mental disease with unknown aetiology. Recent pre-clinical and clinical studies have suggested that the receptor tropomyosin related kinase B (TrkB) and its ligand, brain derived neurotrophic factor (BDNF), play essential roles in the pathogenesis and treatment of major depression. BDNF-TrkB pathway down-regulation may be the most important cause of major depression, while treatments that activate this pathway may improve depressive symptoms. Antidepressants, the main biological treatment for major depression, have been reported to increase central BDNF levels. However, a substantial proportion of depressed patients do not improve clinically despite appropriate antidepressant treatment and, in rare cases, antidepressants can induce or increase suicidal tendencies. In this report, several possible mechanisms relating to BDNF-TrkB signaling are proposed to account for these adverse effects of antidepressants. In addition, several strategies that may increase BDNF-TrkB signaling are proposed for the improved treatment of major depression.
Export Options
About this article
Cite this article as:
Tsai Shih-Jen, A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression, Current Signal Transduction Therapy 2007; 2 (3) . https://dx.doi.org/10.2174/157436207781745319
DOI https://dx.doi.org/10.2174/157436207781745319 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Mesenchymal Stem Cells: Potential in Treatment of Neurodegenerative Diseases
Current Stem Cell Research & Therapy Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological Perspectives
Current Alzheimer Research Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry AMPA Glutamate Receptors and Neuropathic Pain
Mini-Reviews in Medicinal Chemistry Subject Index to Volume 9
Current Pharmaceutical Design Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?
Current Alzheimer Research Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design